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Context: Cytochrome P450 side-chain cleavage enzyme (CYP11A1) catalyses the first and rate-limiting
step of steroidogenesis, the conversion of cholesterol to pregnenolone. CYP11A1 deficiency is
commonly associated with adrenal insufficiency, and in 46,XY individuals, with variable degrees of
disorder of sex development (DSD).
Patient and methods: The patient was born with hyperpigmentation, micropenis, penoscrotal
hypospadias, and mild cryptorchidism. Biochemical and hormonal findings were normal except for
low testosterone and low-borderline cortisol. However, no short synacthen test was undertaken.
Development was unremarkable apart from an episode labeled as sepsis with documented
hyperkalemia and elevated C-reactive protein at age 15 days. Diagnosis of 46,XY DSD was made at
age 2.5 months. Progression of hyperpigmentation prompted further investigations and the diagnosis
of adrenal insufficiency was established at 2 years with raised ACTH, normal renin activity, and failure
of cortisol to respond to short synacthen test. Genetic analyses were performed. The novel CYP11A1
mutations were characterized in vitro and in silico.
Results: The patient was compound heterozygous for two novel CYP11A1 mutations, p.R360W and
p.R405X. p.R360W retained 30–40% of wild-type activity. In silico analyses confirmed these findings
and indicated that p.R405X is severe.
Conclusions: This study demonstrates the pathogenicity of two novel CYP11A1 mutations found in a
patient with delayed diagnosis of CYP11A1 deficiency. Patients with partial deficiencies of
steroidogenic enzymes are at risk to be misdiagnosed if adrenal function is not assessed. The
adrenocortical function should be routinely assessed in all patients with DSD including severe
hypospadias of unknown origin to prevent life-threatening adrenal crises.
European Journal of Endocrinology 167 881–885Introduction
The activity of Cytochrome P450 side-chain cleavage
enzyme (CYP11A1, EC 1.14.15.6) is the prerequisite for
all mineralocorticoid, glucocorticoid, and sex steroid
biosynthesis as it catalyzes its first step, the conversion
of cholesterol to pregnenolone (1). It is encoded by the
CYP11A1 gene, localized on the longarm of chromosome
15 (15q23–q24). CYP11A1 synthesizes pregnenolone
from cholesterol in three consecutive catalytic steps:
20a-hydroxylation, 22R-hydroxylation, and cleavage
of the C20–C22 carbon side chain of cholesterol (1).
Only 11 patients with CYP11A1 deficiency (OMIM
#118485) have been reported so far. The clinical
phenotype is similar to congenital lipoid adrenal
hyperplasia (CLAH; OMIM #201710) that is caused byndocrinology
e distributed under the terms of the European J
nd reproduction in any medium, provided the orideficient mitochondrial cholesterol import due to
mutations in the steroidogenic acute regulatory protein
(STAR) (2). Severe CYP11A1 deficiency manifests with
female external genitalia irrespective of chromosomal sex
and with early onset adrenal insufficiency, usually
manifesting within the first hours or days of life (3, 4).
A milder form of CYP11A1 deficiency has also been
described, associated with delayed onset of adrenal
insufficiency and variable degrees of 46,XY disorder of
sex development (DSD) (5, 6, 7, 8, 9) or also normal male
genital development (10). Adrenal glands are normal size
or absent in CYP11A1 deficiency (10, 11), in contrast to
CLAH (2, 12, 13, 14). In vitro expression studies
assessing the residual activity of mutant CYP11A1
suggest that, overall, the genotype correlates well with
the degree and onset of adrenal insufficiency (10).DOI: 10.1530/EJE-12-0450
Online version via www.eje-online.org
ournal of Endocrinology’s Re-use Licence which permits unrestricted non-
ginal work is properly cited.
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adrenal insufficiency in a patient manifesting at birth
with severe penoscrotal hypospadias and inadequate
adrenal steroidogenesis caused by two novel CYP11A1
mutations. Our data highlights the importance of
considering adrenal insufficiency in the differential
diagnosis of 46,XY DSD patients. Adrenal function
should be assessed in cases with suspicion of adrenal
insufficiency to prevent life-threatening adrenal crises.Patient, materials, and methods
Case report
The patient was born at term to non-consanguineous
parents of Chinese origin. At 12-week gestation, an
episode of threatened miscarriage occurred and the
mother was treated with progesterone injections. At
birth, the child presented with micropenis (1!0.6 cm),
penoscrotal hypospadias, chordee, and mild cryptor-
chidism; in addition, generalized hyperpigmentation was
noted. Further investigations revealed a 46,XYkaryotype.
On day 2, serum testosterone was normal
(3.6 nmol/l; normal reference range (NR), 3.0–12.0)
and dropped to 1.7 nmol/l on day 9. On day 9, plasma
ACTH and 17-hydroxyprogesterone (17OHP) concen-
trations were normal (Table 1). Baseline cortisol was
low (52 nmol/l on a random afternoon sample; normal,
NR: 64–327) and increased to 455 nmol/l during a
urinary tract infection (UTI) at 2 weeks of age that was
associated with increased C-reactive protein (55.7 mg/l;
normal, !5) and hyperkalemia (6.9 mmol/l; normal,
3.5–5.1) with mildly decreased sodium (132 mmol/l;
normal, 136–145) and normal plasma glucose
(74 mg/dl). Electrolytes were within normal range
after the UTI episode and on follow-up measurements
at 4 and 7 months of age.
At 2.5 months, a human chorionic gonadotropin
stimulation test confirmed gonadal dysfunction with
insufficient response of androstenedione (!0.4 nmol/l)
and testosterone (0.7 nmol/l). At this time, cortisolTable 1 Hormonal and biochemical findings at birth and at the time
of diagnosis before treatment initiation.
At birth
(day 9; NR)
At 2 years
Basal (NR) Stimulated
ACTH (pmol/l) 6.5 (!10.1) 565 (!10.1)
Cortisol (nmol/l) 52 (67–327) 54 (138–635) 64
Progesterone (nmol/l) 5.9 (0.7–4.3) !0.1 (0.2–1.7)
17OHP (nmol/l) 1.5 (0.5–20) 0.9 (!3) 0.9
Plasma renin activity
(ng/ml per h)
8.34 (1.7–11.2)
Aldosterone (pmol/l) 3479 (190–5100) 223 (140–2220)
Testosterone (nmol/l) 1.7 (3.0–12) !0.4 (0.1–0.5)
LH (IU/l) 2.3 (1.7–8.6) 7.3 (!1.3)
FSH (IU/l) 7.5 (1.5–12.4) 27.3 (0.2–2.8)
NR, normal reference range; 17OHP, 17-hydroxyprogesterone.
www.eje-online.orgconcentration on a random blood sample was normal
(193 nmol/l on a random morning sample; NR:
138–635) but neither basal ACTH was measured nor a
short synacthen test was performed. Ultrasound demon-
strated the right testis low in the inguinal canal and the
left testis within the scrotum. Small echogenic foci in the
ultrasound were suggestive of testicular microlithiases.
Adrenal glands were of normal size and appearance.
Diagnosis of 46,XY DSDwasmade based on these clinical
and biochemical findings.
Penile length increased to 2.2 cm after initiation on
i.m. injections of testosterone (25 mg) every 4 weeks
over a period of 3 months from the age of 10 months.
Uneventful bilateral orchidopexy was performed at the
age of 15 months.
At the age of 2 years, a progression of the generalized
hyperpigmentation was noted, now with involvement
of the mucosa. The patient was referred to a pediatric
endocrinologist and adrenal insufficiency was suspected.
ACTH levels were elevated (565 pmol/l; normal,!10.1).
A short synacthen test revealed low basal and stimulated
cortisol, 17OHP, and progesterone concentrations
(Table 1). There was no clinical evidence of salt loss.
Aldosterone, plasma renin activity, and electrolytes
(sodium, 139 mmol/l; NR: 136–145 mmol/l; potassium,
4.6 mmol/l; NR: 3.5–5.7 mmol/l) were within the normal
range (Table 1). The patient was commenced on
hydrocortisone replacement. Six months later, aldosterone
concentrations dropped to 127 pmol/l (NR: 140–2220)
with mid normal plasma renin activity (6.7 ng/ml per h;
NR:1.7–11.2)andfludrocortisone treatmentwas initiated.DNA analysis
Molecular genetic analysis of the coding sequence
and exon–intron boundaries of the SF1, STAR, and
CYP11A1 geneswas performed after obtaining informed
consent from the parents and approved by the Local
Ethics Committee. Exons 6 and 7 of the CYP11A1 gene
were PCR amplified and sequenced in the parents for
segregation analysis. DNAwas extracted from peripheral
blood leukocytes following standard procedures.
Sequence variants were designated according to
Human Genome Variation Society recommendations
(www.hgvs.org/rec.html) using the following reference
sequences: GenBank, NG_007973 (gDNA); GenBank,
NM_000781.2 (cDNA); and GenBank, NP_000772.2
(protein). The location of the first nucleotide used for
gDNA and cDNA numbering is the A of the ATG
translation initiation codon of the reference sequence.In vitro characterization of mutant CYP11A1
activity
The in vitro analysis of the p.R360W mutation
was performed as described previously (10). In
brief, the p.R360W mutation was recreated in the
pcDNA6-CYP11A1 vector by site-directed mutagenesis
Mild CYP11A1 deficiency: two novel mutations 883EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 167following a standard protocol (QuickChange XL
Site-Directed Mutagenesis Kit, Stratagene, Amsterdam,
The Netherlands). The pcDNA6-CYP11A1 vector
contains the coding DNA sequence of wild-type
CYP11A1 with a 14 amino acids sequence tag
(V5-tag, GKPIPNPLLGLDST) at the 3 0-terminus.
CYP11A1 enzyme activity was assessed by
measuring the conversion of cholesterol and
22R-hydroxycholesterol, respectively, into pregneno-
lone. 22R-hydroxycholesterol is an intermediate
product not relying on STAR-mediated transport to
enter the mitochondria. Thereby, it allowed measuring
CYP11A1 activity STAR-independent. COS7 cells were
transiently co-transfected with 1 mg wild-
type or mutant pcDNA6-CYP11A1, 0.5 mg wild-type
STAR cDNA (pcDNA6-STAR), and 0.5 mg bovine
adrenodoxin cDNA (pBAdx4, kindly provided by Prof.
M RWaterman, Department of Biochemistry, Vanderbilt
University School of Medicine, Nashville, Tennessee).
STAR was not overexpressed for the activity assay
measuring the conversion of 22R-hydroxycholesterol
to pregnenolone. pcDNA6/V5-HisB empty vector was
used as a negative control.
Forty-eight hours after transfection, cells were
incubated with either 2.5 mmol/l cholesterol or
2 mmol/l 22R-hydroxycholesterol for 24 or 4 h respect-
ively. Conversion of these substrates into pregnenolone
was measured by liquid chromatography/tandem mass
spectrometry. Mutant CYP11A1 activity was expressed
as a percentage of substrate conversion in micromoles
per milligram of total protein per minute, defining wild-
type activity as 100%. Assays were performed in at least
three independent triplicate experiments, and data are
presented as meanGS.E.M. using the GraphPad Prism
Software version 5.0 (GraphPad, Inc., San Diego, CA,
USA). Western blot analysis was performed using 8 mg
of total protein and 1 mg/ml anti-V5 mouse antibody.Figure 1 In vitro and in silico analysis of the two novel CYP11A1
mutations. (A) CYP11A1 residual enzyme activity obtained for the
conversion of cholesterol and 22R-hydroxycholesterol at a sub-
strate concentration of 2.5 and 2 mmol/l. Residual enzyme activity is
expressed as percentage of wild-type (WT) activity, which is defined
as 100%. Assays were performed in triplicate in three independent
experiments. Error bars indicate meanGS.E.M. (%). (B) Represen-
tative western blot using anti-V5 antibody to detect expression ofIn silico analysis of the novel CYP11A1
mutations
The crystal structure of human CYP11A1 (http://www.
rcsb.org/pdb, PDB code 3NA0) was used to analyze the
impact of the p.R360W and p.R405X mutations on the
three-dimensional structure of the CYP11A1 enzyme
using the Molsoft ICM Browser Pro Software (Molsoft
L.L.C, La Jolla, CA, USA).wild-type (WT) and mutant CYP11A1 tagged with V5 at the
C-terminus and the pcDNA6/V5-HisB empty vector (EV). An anti-
b-actin antibody was used to assure equivalent protein load for WT,
mutant, and EV. (C, D and E) Three-dimensional molecular model
of CYP11A1. (C) Localization of the two novel CYP11A1 mutations
on the crystal structure of human CYP11A1 (http://www.rcsb.org/
pdb, PDB code 3NA0). (D) Localization of the R360 residue and
polarity of the protein surface when an arginine is present at this
position. (E) Polarity change on the protein surface induced by a
tryptophan at residue 360. N-term, amino terminus; C-term, carboxy
terminus. The I-helix is colored in red, the L-helix in light blue, the
K-helix in dark blue, and the cysteine pocket in green. The structural
representations were generated using Molsoft ICM Browser Pro.Results
As a first step, based on the incidence of mutations
in SF1 or STAR associated with AI and 46,XY DSD, the
mutation analysis of the SF1 and STAR genes was
performed. No disease-causing mutations were found in
either of these candidate genes. The CYP11A1 mutation
analysis was performed as the next diagnostic
procedure. Two novel CYP11A1 mutations werewww.eje-online.org
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position 27 921 (c.1078COT, p.R360W) on the
maternal allele and a cytosine to thymine transition
at nucleotide position 28 327 (c.1213COT, p.R405X)
on the paternal allele.
The p.R360W mutation retained 38 and 30% of
wild-type CYP11A1 in vitro activity for the conversion
of cholesterol and 22R-hydroxycholesterol to pregne-
nolone respectively (Fig. 1A). Western blot analyses
consistently showed lower protein levels for the
p.R360W mutation than for the wild-type, suggesting
that p.R360W may impair protein stability, also
indicated by consistent evidence of protein degradation
in the mutant protein blots (Fig. 1B).
The arginine residue at position 360 of the
CYP11A1 protein is highly conserved across species,
but not across mitochondrial cytochrome P450 (CYP)
type I enzymes (Fig. 2). This residue is localized at the
amino-terminus of the J-helix. Substitution of a positive-
charged arginine by an aliphatic nonpolar tryptophanFigure 2 ClustalW alignment of the two novel CYP11A1 mutations
found in a patient with mild CYP11A1 deficiency. (A) Alignment of
human CYP11A1 with ortholog proteins from another species. (B)
Alignment of hCYP11A1 with other human mitochondrial cyto-
chrome P450 type I enzymes. The R360 and R405 are shaded and
marked by a triangle.
www.eje-online.orgresults in a polarity change on the protein surface, but
otherwise no major structural changes were apparent
(Fig. 1C, D and E).
The arginine at codon405 is notwell conserved (Fig. 2)
and localizes to theC-terminal part of the loopbetween the
b2-1 and b2-2 sheets (Fig. 1C). Apremature truncation of
the protein at this position eliminates protein domains
crucial for CYP11A1 activity (15). Therefore, the novel
nonsense p.R405X mutation is predicted to result in a
complete loss of CYP11A1 function.Discussion
Herein, we present a case of delayed diagnosis of adrenal
insufficiency in a patient with penoscrotal hypospadias
caused by two novel CYP11A1 mutations, p.R360W
and p.R405X. In vitro and in silico analyses were
consistent with the clinical findings and confirmed the
diagnosis of CYP11A1 deficiency in the patient. This
report demonstrates that diagnosis of CYP11A1
deficiency can be challenging and highlights the
importance of adrenal function assessment to provide
adequate clinical diagnosis and to prevent life-threaten-
ing adrenal crises.
Partially CYP11A1 inactivating mutations are usually
associatedwith onset of adrenal insufficiency between the
age of 2 and 9 years (7, 8, 9, 10). Earlier onset of adrenal
symptoms has been reported in a patient compound
heterozygote for the mild p.L141W and the severe
p.V415E mutations (4). Signs and symptoms suggest
that adrenal steroidogenesis was already partially
impaired in our patient soon after birth, with generalized
hyperpigmentation, low cortisol levels, and insufficient
cortisol response during a UTI sepsis episode. Further-
more, it is tempting to speculate that the episode of
premature labor at 12 weeks of gestation may be due to
insufficient placental CYP11A1 activity (16).
Our current data together with previous findings (4)
suggest that compound heterozygosity for a mild and a
severe mutation may advance onset of signs and
symptoms of impaired adrenal function in patients with
mild CYP11A1 deficiency. The diagnosis of adrenal
insufficiency can be missed by normal baseline cortisol
concentrations and lack of adequate adrenal function
assessment. Similarly, to our previous report of two
siblings with partial CYP11A1 deficiency (10), our
patient had normal plasma renin activity at the age of 2
years when not stressed.Mild CYP11A1 deficiencycan be
therebymisdiagnosedas familial glucocorticoiddeficiency
in46,XXpatients and46,XYpatientswithnoor verymild
DSD and apparently normal mineralocorticoid activity.
Prenatally, partial impairment of pregnenolone
synthesis is associated with a broad phenotypic
spectrum with regard to genital presentation (11) and
postnatally with gonadal insufficiency (7, 4, 10).
Similarly to other inborn errors of steroidogenesis
such as CLAH (13) and HSD3B2 deficiency (17), the
Mild CYP11A1 deficiency: two novel mutations 885EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 167CYP11A1 genotype correlates poorly with the pheno-
type of the external genitalia. CYP11A1 mutations with
residual enzyme activities similar to p.R360W were
associated with either normal female external genitalia
in 46,XY patients (p.L141W and p.A359V) (4, 7) or
normal male genital development (p.R451W) (10). The
moderate degree of 46,XY DSD in our patient indicates
that gonadal steroidogenesis was only partly impaired
during early development. However, increased gonado-
tropin levels at age 2 years suggest progressive loss of
Leydig cell function. The reassessment of gonadal
function at early puberty and clinical follow-up will be
essential to assess the requirements for sex hormone
replacement during puberty and the potential for
fertility in our patient.
We describe two novel CYP11A1 mutations, p.R360W
and p.R405X, associated with early onset and mild
adrenal insufficiency and moderate 46,XY DSD. Our
data demonstrate the partially inactivating nature of the
novel p.R360W mutation. Importantly, this report
exemplifies the importance to properly assess adrenal
function at the time of first clinical presentation to ensure
timely diagnosis of patients with mild inborn and possibly
progressively developing adrenal insufficiency. Adrenal
insufficiency must be considered in the differential
diagnosis of patientspresentingwith46,XYDSD including
severe hypospadias to establish an early correct diagnosis
and to prevent potential life-threatening adrenal crises.Declaration of interest
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